News stories about Aldeyra Therapeutics (NASDAQ:ALDX) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aldeyra Therapeutics earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.785210199661 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Aldeyra Therapeutics (ALDX) traded down 1.9385% on Thursday, hitting $4.7805. The stock had a trading volume of 16,269 shares. The company has a 50 day moving average of $4.77 and a 200 day moving average of $4.87. Aldeyra Therapeutics has a 12-month low of $3.80 and a 12-month high of $8.19. The company’s market capitalization is $29.85 million.
Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Monday, May 15th. The biotechnology company reported ($0.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by $0.04. On average, equities analysts expect that Aldeyra Therapeutics will post ($1.58) earnings per share for the current year.
A number of research analysts have commented on ALDX shares. Cowen and Company reiterated a “buy” rating and issued a $20.00 price objective on shares of Aldeyra Therapeutics in a research report on Friday, March 31st. Stifel Nicolaus reiterated a “buy” rating and issued a $16.00 price objective on shares of Aldeyra Therapeutics in a research report on Wednesday, May 31st. Zacks Investment Research lowered Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, May 30th. HC Wainwright set a $18.00 price objective on Aldeyra Therapeutics and gave the company a “buy” rating in a research report on Thursday, June 15th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $12.00 price objective (down from $15.00) on shares of Aldeyra Therapeutics in a research report on Friday, March 31st. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $14.30.
TRADEMARK VIOLATION NOTICE: “Aldeyra Therapeutics (ALDX) Earns Media Sentiment Score of 0.20” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://sportsperspectives.com/2017/07/20/aldeyra-therapeutics-aldx-earns-media-sentiment-score-of-0-20.html.
In related news, major shareholder Life Sciences Maste Perceptive acquired 296,007 shares of the firm’s stock in a transaction that occurred on Friday, June 30th. The stock was acquired at an average cost of $4.60 per share, for a total transaction of $1,361,632.20. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 28.40% of the company’s stock.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.